Analysts Set Valeritas Holdings Inc (VLRX) PT at $2.50
Valeritas Holdings Inc (NASDAQ:VLRX) has earned a consensus rating of “Buy” from the six analysts that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $2.50.
Several brokerages have commented on VLRX. Oppenheimer set a $2.00 target price on Valeritas and gave the stock a “buy” rating in a research note on Wednesday, November 21st. BTIG Research began coverage on Valeritas in a research note on Tuesday. They issued a “buy” rating and a $1.00 price objective for the company.
In other news, major shareholder Armistice Capital Master Fund purchased 350,000 shares of the business’s stock in a transaction dated Monday, November 26th. The stock was bought at an average price of $0.38 per share, for a total transaction of $133,000.00. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders have bought a total of 630,000 shares of company stock valued at $241,900 in the last quarter. 1.80% of the stock is owned by corporate insiders.
NASDAQ:VLRX opened at $0.35 on Tuesday. The company has a debt-to-equity ratio of 13.66, a current ratio of 3.00 and a quick ratio of 2.47. Valeritas has a 1-year low of $0.34 and a 1-year high of $4.72. The firm has a market capitalization of $9.39 million, a P/E ratio of -0.04 and a beta of 2.22.
Valeritas (NASDAQ:VLRX) last posted its quarterly earnings results on Friday, November 9th. The company reported ($0.49) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.56) by $0.07. The business had revenue of $6.93 million during the quarter. Valeritas had a negative return on equity of 1,768.69% and a negative net margin of 193.79%. As a group, sell-side analysts anticipate that Valeritas will post -1.3 EPS for the current year.
Valeritas Company Profile
Valeritas Holdings, Inc, a commercial-stage medical technology company, focuses on the development and commercialization of technologies to treat patients with Type 2 diabetes in the United States and China. It offers V-Go, a wearable insulin delivery device for basal-bolus therapy. The company also develops h-Patch, a controlled delivery technology platform; Mini-Ject technology for needle-free injection systems; and Micro-Trans technology for microneedle design, fabrication, and drug delivery.
Receive News & Ratings for Valeritas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeritas and related companies with MarketBeat.com's FREE daily email newsletter.